Developer docs
API playgroundTry for free, no card

Search company profiles

SmartCatch

Full company profile

uuid00039kp

Namestring
SmartCatch
Legal namestring
SMARTCATCH
Websiteurl
smartcatch.fr
Company typeenum
Private
Founded yearint
2016
Descriptiontext

SmartCatch is a French medtech company headquartered in Toulouse, France, that designs and manufactures microfiltration-based devices for the isolation of circulating tumor cells (CTCs) from whole blood. Founded in September 2016 as a spin-off of CNRS, the company was created jointly by an academic micro/nanotechnology team from LAAS-CNRS and urology surgeons from the University Institute of Cancer (IUCT) and Montauban Uropole, after 7 years of collaborative R&D. The commercial product portfolio comprises three offerings: CTC-Station (benchtop instrument for research use and drug development), CTC-Pheresis (portable system for clinical routine use, prognosis, and treatment monitoring), and X-Tracker (a fully-automated benchtop system for single-step CTC enrichment from 6-45 ml of untreated biofluid). Underlying technology relies on proprietary microengineered 3D traps that exploit physical differences between CTCs and normal blood cells (larger size, lower deformability) to enable one-step, label-free isolation under physiological conditions without pre-analytical steps. The technology also incorporates bio-impedance spectroscopy via a micro-perforated sensing membrane for retained cell detection.

The business model is B2B hardware sales of specialized laboratory instruments and consumable capture devices, with pricing that is quote-based and negotiated directly with research and clinical buyers; no public price list exists. Revenue is generated by deploying instruments and consumables into academic research centers, clinical research institutes, and pharmaceutical companies, with the go-to-market executed via consultative, technical enterprise field sales supported by peer-reviewed publications, conference participation (e.g., Hello Tomorrow Global Summit, Prix Galien USA Awards nomination in 2024), and professional network engagement. The company has raised EUR 3.2 million in seed financing from Kurma Partners, IRDI Capital Investissement, and M-Capital, and operates with approximately 9 personnel covering R&D, industrial operations, regulatory affairs, and commercial leadership. A CINTLPHARMA partnership signed in July 2025 extends the platform into precision oncology and pharmaceutical applications.

Strategically, SmartCatch's competitive position is anchored on a physically differentiated CTC capture approach that addresses limitations of existing isolation methods (complexity, cost, loss of cell viability) and a founding team that combines clinical oncology domain expertise with academic microtechnology capability. Key constraints are the early commercial stage, research-use labeling on certain products, absence of disclosed revenue or recurring customer logos, and concentration of operating geography in France with emerging activity in Mexico.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersToulouse, France
HQ citystring
Toulouse
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
liquid biopsy devices, circulating tumor cells, microfiltration instruments, cancer diagnostics, CTC isolation technology
Industry4 codes
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAAMAH
Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
NAICS code3 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Analytical Laboratory Instrument Manufacturing334516
  • Surgical Appliance and Supplies Manufacturing339113
SIC code3 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Surgical & Medical Instruments & Apparatus3841
  • Laboratory Analytical Instruments3826
Product category
Liquid Biopsy Medical Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Medical Device Sales
TypeHardware Sales
Description

SmartCatch generates revenue through the sale of specialized medical laboratory equipment including the X-Tracker benchtop system and consumable capture devices. The company targets academic research centers and clinical research institutions with hardware products for cancer diagnostics and research applications.

smartcatch.fr
2Research Equipment
TypeHardware Sales
Description

Sale of laboratory instruments adapted for clinical routine use, including compact and portable products for CTC liquid biopsy applications. The X-Tracker is deployed into academic research centers and clinical research institutes for research purposes.

smartcatch.fr
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Supply Chain, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

SmartCatch designs and manufactures microfiltration-based medical devices for isolating circulating tumor cells (CTCs) directly from whole blood without pre-analytical steps. The product line includes the X-Tracker automated benchtop system, CTC-Station benchtop instrument, and CTC-Pheresis portable system, targeting academic research centers, clinical research institutes, and pharmaceutical companies for cancer diagnostics, treatment monitoring, and oncology research.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • CTC isolation from fresh blood samples without pre-treatment, yielding unaltered/viable cells in minutes
+1 more record
Product overview1 text field

SmartCatch offers a portfolio of microfiltration-based medical devices for circulating tumor cell (CTC) isolation and analysis. The product line centers on three offerings: X-Tracker (an automated benchtop system for CTC enrichment), CTC-Station (a benchtop instrument for research applications), and CTC-Pheresis (a portable system for clinical routine). All products leverage proprietary microtechnology to capture CTCs directly from whole blood without pre-analytical steps, maintaining cell viability for downstream molecular analysis.

Product and service3 records
1X-Tracker
CategoryLiquid Biopsy Medical Device
Description

Fully-automated benchtop system that reproduces in vivo conditions to ensure optimal capture of circulating tumor cells from blood samples (6-45 ml) without pre-treatment, for subsequent multi-omic analysis including proteomics, transcriptomics, and functional studies. Designed for research and clinical routine use in academic and clinical settings.

2CTC-Station
CategoryLiquid Biopsy Medical Device
Description

Benchtop instrument for isolating circulating tumor cells from whole blood using microfiltration technology, designed for research use in studying tumor biology and accelerating drug development in academic and pharmaceutical research settings.

3CTC-Pheresis
CategoryLiquid Biopsy Medical Device
Description

Portable system for clinical routine use, enabling prognosis and real-time monitoring of cancer treatment through circulating tumor cell analysis. Designed for hospital and clinical research deployment.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-07-28
Description

New partnership signed in July 2025 to strengthen work in precision oncology and expand the use of SmartCatch's CTC technology for better cancer diagnosis and monitoring. This collaboration supports the company's mission to make liquid biopsy accessible while expanding into pharmaceutical applications.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Developer of CELLSEARCH, the first and only FDA-cleared CTC enumeration platform for metastatic breast, prostate, and colorectal cancer. Most direct competitor in CTC isolation with significantly larger commercial scale and clinical evidence base.

TypeDirect peer
Description

UK-based liquid biopsy company with Parsortix system for CTC isolation from blood, used in research and clinical applications. Competes directly in the microfiltration-based CTC capture space targeted by SmartCatch.

TypeDirect peer
Description

US-based company developing the AccuCyte and RarePlex CTC isolation and analysis platforms for research and clinical oncology applications. Competes in the same CTC liquid biopsy market as SmartCatch with similar research-and-clinical use cases.

4Vortex Biosciences
TypeDirect peer
Description

Developer of the VTX-1 liquid biopsy system for automated CTC isolation using microfluidic technology. Direct competitor in microtechnology-based CTC capture for oncology research and clinical applications.

TypeDirect peer
Description

US-based company with a CTC platform for liquid biopsy applications including treatment monitoring and minimal residual disease detection. Competes in the same precision oncology CTC analysis market.

TypeBroad incumbent
Description

Large life sciences tools company with a portfolio including protein biomarkers, diagnostics, and reagents used in oncology research. Acts as a broad incumbent supplying tools and consumables to the same research customer base as SmartCatch.

TypeBroad incumbent
Description

Global leader in sample preparation and molecular diagnostics with liquid biopsy offerings including circulating nucleic acid isolation kits. Broad incumbent in the liquid biopsy workflow serving the same oncology research and clinical customers.

TypeEmerging player
Description

Early-stage company developing microfluidic CTC isolation platforms for liquid biopsy applications. Similar technology profile to SmartCatch and a comparable emerging player in the rare-cell capture space.

9CytoLumina
TypeEmerging player
Description

Early-stage liquid biopsy company focused on CTC and circulating rare cell isolation. Emerging player with partial overlap in microtechnology-based CTC capture applications.

TypeOthers
Description

Provider of cell separation and analysis technologies including MACS-based CTC isolation kits for research use. Adjacent technology provider and ecosystem participant serving the same oncology research customers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SmartCatch

Liquid Biopsy Medical Devicessmartcatch.fr

What SmartCatch does

SmartCatch is a French medtech company headquartered in Toulouse, France, that designs and manufactures microfiltration-based devices for the isolation of circulating tumor cells (CTCs) from whole blood. Founded in September 2016 as a spin-off of CNRS, the company was created jointly by an academic micro/nanotechnology team from LAAS-CNRS and urology surgeons from the University Institute of Cancer (IUCT) and Montauban Uropole, after 7 years of collaborative R&D. The commercial product portfolio comprises three offerings: CTC-Station (benchtop instrument for research use and drug development), CTC-Pheresis (portable system for clinical routine use, prognosis, and treatment monitoring), and X-Tracker (a fully-automated benchtop system for single-step CTC enrichment from 6-45 ml of untreated biofluid). Underlying technology relies on proprietary microengineered 3D traps that exploit physical differences between CTCs and normal blood cells (larger size, lower deformability) to enable one-step, label-free isolation under physiological conditions without pre-analytical steps. The technology also incorporates bio-impedance spectroscopy via a micro-perforated sensing membrane for retained cell detection.

The business model is B2B hardware sales of specialized laboratory instruments and consumable capture devices, with pricing that is quote-based and negotiated directly with research and clinical buyers; no public price list exists. Revenue is generated by deploying instruments and consumables into academic research centers, clinical research institutes, and pharmaceutical companies, with the go-to-market executed via consultative, technical enterprise field sales supported by peer-reviewed publications, conference participation (e.g., Hello Tomorrow Global Summit, Prix Galien USA Awards nomination in 2024), and professional network engagement. The company has raised EUR 3.2 million in seed financing from Kurma Partners, IRDI Capital Investissement, and M-Capital, and operates with approximately 9 personnel covering R&D, industrial operations, regulatory affairs, and commercial leadership. A CINTLPHARMA partnership signed in July 2025 extends the platform into precision oncology and pharmaceutical applications.

Strategically, SmartCatch's competitive position is anchored on a physically differentiated CTC capture approach that addresses limitations of existing isolation methods (complexity, cost, loss of cell viability) and a founding team that combines clinical oncology domain expertise with academic microtechnology capability. Key constraints are the early commercial stage, research-use labeling on certain products, absence of disclosed revenue or recurring customer logos, and concentration of operating geography in France with emerging activity in Mexico.

SmartCatch firmographics

Firmographics
Name
SmartCatch
Legal name
SMARTCATCH
Website
https://smartcatch.fr
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

SmartCatch industry classification

Industry
Product category
Liquid Biopsy Medical Devices
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516), Surgical Appliance and Supplies Manufacturing (339113)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAAMAH
Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

Keywords

  • Liquid biopsy devices
  • Circulating tumor cells
  • Microfiltration instruments
  • Cancer diagnostics
  • CTC isolation technology

Where SmartCatch is headquartered

Location

Headquarters

HQ city
Toulouse
HQ country
France
HQ region
Europe

Offices1 record

Markets served

SmartCatch business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Operations

Revenue model

  1. Medical Device Sales: SmartCatch generates revenue through the sale of specialized medical laboratory equipment including the X-Tracker benchtop system and consumable capture devices. The company targets academic research centers and clinical research institutions with hardware products for cancer diagnostics and research applications.
  2. Research Equipment: Sale of laboratory instruments adapted for clinical routine use, including compact and portable products for CTC liquid biopsy applications. The X-Tracker is deployed into academic research centers and clinical research institutes for research purposes.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

SmartCatch product offering

Product offering

Core offering

SmartCatch designs and manufactures microfiltration-based medical devices for isolating circulating tumor cells (CTCs) directly from whole blood without pre-analytical steps. The product line includes the X-Tracker automated benchtop system, CTC-Station benchtop instrument, and CTC-Pheresis portable system, targeting academic research centers, clinical research institutes, and pharmaceutical companies for cancer diagnostics, treatment monitoring, and oncology research.

Product overview

SmartCatch offers a portfolio of microfiltration-based medical devices for circulating tumor cell (CTC) isolation and analysis. The product line centers on three offerings: X-Tracker (an automated benchtop system for CTC enrichment), CTC-Station (a benchtop instrument for research applications), and CTC-Pheresis (a portable system for clinical routine). All products leverage proprietary microtechnology to capture CTCs directly from whole blood without pre-analytical steps, maintaining cell viability for downstream molecular analysis.

Differentiator

Problem solved

Functional benefit

Products and services

  • X-Tracker Fully-automated benchtop system that reproduces in vivo conditions to ensure optimal capture of circulating tumor cells from blood samples (6-45 ml) without pre-treatment, for subsequent multi-omic analysis including proteomics, transcriptomics, and functional studies. Designed for research and clinical routine use in academic and clinical settings.
  • CTC-Station Benchtop instrument for isolating circulating tumor cells from whole blood using microfiltration technology, designed for research use in studying tumor biology and accelerating drug development in academic and pharmaceutical research settings.
  • CTC-Pheresis Portable system for clinical routine use, enabling prognosis and real-time monitoring of cancer treatment through circulating tumor cell analysis. Designed for hospital and clinical research deployment.

Quantifiable outcome

  • CTC isolation from fresh blood samples without pre-treatment, yielding unaltered/viable cells in minutes
  • +1 more outcomes

Companies that use SmartCatch

Customer profile

Segments3 records

Ideal customer profiles3 records

SmartCatch technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

SmartCatch partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • CINTLPHARMAcoreStrategic or Co-development Partner · 28 July 2025New partnership signed in July 2025 to strengthen work in precision oncology and expand the use of SmartCatch's CTC technology for better cancer diagnosis and monitoring. This collaboration supports the company's mission to make liquid biopsy accessible while expanding into pharmaceutical applications.

Scale indicators3 records

Recent moves7 records

Expansion highlights6 records

SmartCatch competitors and assessment

Company assessment

Direct peers

  • Menarini Silicon Biosystems: Developer of CELLSEARCH, the first and only FDA-cleared CTC enumeration platform for metastatic breast, prostate, and colorectal cancer. Most direct competitor in CTC isolation with significantly larger commercial scale and clinical evidence base.
  • ANGLE plc: UK-based liquid biopsy company with Parsortix system for CTC isolation from blood, used in research and clinical applications. Competes directly in the microfiltration-based CTC capture space targeted by SmartCatch.
  • RareCyte: US-based company developing the AccuCyte and RarePlex CTC isolation and analysis platforms for research and clinical oncology applications. Competes in the same CTC liquid biopsy market as SmartCatch with similar research-and-clinical use cases.
  • Vortex Biosciences: Developer of the VTX-1 liquid biopsy system for automated CTC isolation using microfluidic technology. Direct competitor in microtechnology-based CTC capture for oncology research and clinical applications.
  • EPIC Sciences: US-based company with a CTC platform for liquid biopsy applications including treatment monitoring and minimal residual disease detection. Competes in the same precision oncology CTC analysis market.

Broad incumbents

  • Bio-Techne: Large life sciences tools company with a portfolio including protein biomarkers, diagnostics, and reagents used in oncology research. Acts as a broad incumbent supplying tools and consumables to the same research customer base as SmartCatch.
  • QIAGEN: Global leader in sample preparation and molecular diagnostics with liquid biopsy offerings including circulating nucleic acid isolation kits. Broad incumbent in the liquid biopsy workflow serving the same oncology research and clinical customers.

Emerging players

  • BioFluidica: Early-stage company developing microfluidic CTC isolation platforms for liquid biopsy applications. Similar technology profile to SmartCatch and a comparable emerging player in the rare-cell capture space.
  • CytoLumina: Early-stage liquid biopsy company focused on CTC and circulating rare cell isolation. Emerging player with partial overlap in microtechnology-based CTC capture applications.

Others

  • Miltenyi Biotec: Provider of cell separation and analysis technologies including MACS-based CTC isolation kits for research use. Adjacent technology provider and ecosystem participant serving the same oncology research customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

SmartCatch social profiles

Digital presence

SmartCatch financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SmartCatch leadership team

Management profile

Number of profiles

Profiles1 record

SmartCatch funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SmartCatch M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SmartCatch

What does SmartCatch do?

SmartCatch designs and manufactures microfiltration-based medical devices for isolating circulating tumor cells (CTCs) directly from whole blood without pre-analytical steps. The product line includes the X-Tracker automated benchtop system, CTC-Station benchtop instrument, and CTC-Pheresis portable system, targeting academic research centers, clinical research institutes, and pharmaceutical companies for cancer diagnostics, treatment monitoring, and oncology research.

Is SmartCatch a public or private company?

SmartCatch is a private company. It is classified as venture growth investor backed and is currently operating.

When was SmartCatch founded?

SmartCatch was founded in 2016. It employs 11 to 50 people.

Where is SmartCatch based?

SmartCatch is headquartered in Toulouse, France, in the Europe region.

How does SmartCatch make money?

Two revenue lines are on record. Medical Device Sales are the primary driver. The others are research Equipment.

Who are SmartCatch's main competitors?

Direct peers on record are Menarini Silicon Biosystems, ANGLE plc, RareCyte, Vortex Biosciences and EPIC Sciences. Broad incumbents are Bio-Techne and QIAGEN. Emerging players are BioFluidica and CytoLumina. Miltenyi Biotec is listed as an others.

Does SmartCatch have an API?

No public API is recorded for SmartCatch.

What industry is SmartCatch in?

SmartCatch's product category is Liquid Biopsy Medical Devices. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAAAMAH, Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals